Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
08:00am, Friday, 18'th Oct 2024
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31,
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
08:00am, Wednesday, 02'nd Oct 2024
CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MAS
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
12:37pm, Friday, 06'th Sep 2024
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Is Madrigal Pharmaceuticals Stock a Buy?
10:15am, Saturday, 17'th Aug 2024
Madrigal Pharmaceuticals earned the first approval for a medicine in an area with a high unmet need. The biotech has more to do to dominate this market, considering it should become more crowded soon.
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
06:00am, Wednesday, 14'th Aug 2024
Novo Nordisk just canceled one of its early-stage clinical programs. Madrigal Pharmaceuticals is a specialist developer for the same target illness.
While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
04:21pm, Thursday, 08'th Aug 2024
Madrigal Pharmaceuticals' Q2 2024 revenue from Rezdiffra exceeded expectations at $14.6 million. The company's SG&A expenses surged to $105.4 million, reflecting launch activities. Over 2,000 patients
Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
12:15pm, Wednesday, 07'th Aug 2024
Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2024 Earnings Call Transcript
11:23am, Wednesday, 07'th Aug 2024
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - CEO, Presiden
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
09:11am, Wednesday, 07'th Aug 2024
Madrigal (MDGL) came out with a quarterly loss of $7.10 per share versus the Zacks Consensus Estimate of a loss of $7.55. This compares to loss of $4.69 per share a year ago.
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
07:00am, Wednesday, 07'th Aug 2024
CONSHOHOCKEN, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis
Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
06:30am, Monday, 05'th Aug 2024
Madrigal Pharmaceuticals is launching its first medicine. It's also the first competitor to enter its market.
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
07:00am, Friday, 02'nd Aug 2024
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
08:00am, Wednesday, 24'th Jul 2024
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August
7 Biotech Stocks to Keep on Your Clinical Radar
02:57pm, Tuesday, 23'rd Jul 2024
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be rel
